FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person Daly Richard J					<u>C</u>	2. Issuer Name and Ticker or Trading Symbol CATALYST PHARMACEUTICALS, INC. CPRX							C. (Ch	elationship eck all appli Directo	•			
(Last) 355 ALH	(F IAMBRA (irst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/04/2024									Officer (give title below) President a		Other (s below)	specify
SUITE 801					4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)														Form 1	iled by Moi		orting Person	- 1
GABLES	S F	L	33134		F	ر مار،	10h	F 1/a	\ Tron		ation Ind	ication		Persor	n			
(City) (State) (Zip)				Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Tal	ole I - N	lon-Deri	ivativ	e Se	curit	ties Ac	quire	d, D	isposed o	f, or Be	neficial	y Owned	i			
1. Title of Security (Instr. 3) 2. Transactic Date (Month/Day/				Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4 and 1)				es ially Following	Form (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership					
							Code	v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)		
Common stock, par value \$0.001 per share 06/04/20				/2024	24		M		40,000	A	\$4.01	252,147			D			
Common stock, par value \$0.001 per share 06/04/20			/2024	24		S		17,323	D	\$15.975	(1) 234	4,824	D					
			Table II								posed of, convertil			Owned				
1. Title of Derivative Security (Instr. 3) 2. Conversion of Exercising Price of Derivative Security		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transa Code (8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	e s lly	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amount or Number of Shares					
Options to purchase common	\$4.01	06/04/2024			M			40,000	(2)		01/02/2025	Common Stock	40,000	\$0	1,731,0	012	D	

Explanation of Responses:

- 1. Shares were sold on the open market in order to fund the exercise price and tax withholding of the exercise of the stock option.
- 2. Derivative securities vested in three annual tranches beginning on January 2, 2019.

/s/ Richard J. Daly 06/05/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.